Mary Thistle
CIK: 0001317917
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (10 total)
- Jun 16, 2026CGEM
Cullinan Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
25.3K shares- - Jun 12, 2026QTTB
Q32 Bio Inc.
Award(A)DirectStock Option (Right to Buy)
10.8K shares- - Jun 12, 2026QTTB
Q32 Bio Inc.
Award(A)DirectStock Option (Right to Buy)
9.8K shares- - Jun 10, 2026TRDA
Entrada Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
19K shares- - Oct 23, 2025QTTB
Q32 Bio Inc.
Award(A)DirectStock Option (Right to Buy)
53.5K shares- - Aug 5, 2025VIGL
Vigil Neuroscience, Inc.
Disposition(D)Direct5K shares- - Jun 11, 2025TRDA
Entrada Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
19K shares- - May 22, 2025VIGL
Vigil Neuroscience, Inc.
Award(A)Direct5K shares- - Feb 24, 2025QTTB
Q32 Bio Inc.
Disposition(D)DirectStock Option (Right to Buy)
12.8K shares- - Feb 24, 2025QTTB
Q32 Bio Inc.
Award(A)DirectStock Option (Right to Buy)
12.8K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 16, 2026 |  CGEM Cullinan Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 25,319 | - | - | Direct |
| Jun 12, 2026 |  QTTB Q32 Bio Inc. | Award(A) Stock Option (Right to Buy) | 10,826 | - | - | Direct |
| Jun 12, 2026 | QTTB Q32 Bio Inc. | Award(A) Stock Option (Right to Buy) | 9,810 | - | - | Direct |
| Jun 10, 2026 |  TRDA Entrada Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 19,000 | - | - | Direct |
| Oct 23, 2025 | QTTB Q32 Bio Inc. | Award(A) Stock Option (Right to Buy) | 53,521 | - | - | Direct |
| Aug 5, 2025 |  VIGL Vigil Neuroscience, Inc. | Disposition(D) | 5,000 | - | - | Direct |
| Jun 11, 2025 | TRDA Entrada Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 19,000 | - | - | Direct |
| May 22, 2025 | VIGL Vigil Neuroscience, Inc. | Award(A) | 5,000 | - | - | Direct |
| Feb 24, 2025 | QTTB Q32 Bio Inc. | Disposition(D) Stock Option (Right to Buy) | 12,767 | - | - | Direct |
| Feb 24, 2025 | QTTB Q32 Bio Inc. | Award(A) Stock Option (Right to Buy) | 12,767 | - | - | Direct |
1-10 of 10 transactions
About Thistle Mary
Thistle Mary (SEC CIK 0001317917) files insider reports with the SEC as Director of Q32 Bio Inc. (QTTB), Director of Cullinan Therapeutics, Inc. (CGEM) and Director of Entrada Therapeutics, Inc. (TRDA). Signal8 also holds filings tied to 2 other companies.
Signal8 holds 10 ownership filings by Thistle Mary (1 Form 3, 9 Form 4), filed between Feb 26, 2025 and Jul 21, 2026. Those filings report 10 transactions, from Feb 24, 2025 to Jun 16, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Thistle Mary's filings is in WALTHAM, MA.
Recent filings by Thistle Mary
- Jun 16, 2026: Grant or award of CGEM derivative securities (Form 4, code A).
- Jun 12, 2026: Grants or awards of QTTB derivative securities (2 lines, Form 4, code A).
- Jun 10, 2026: Grant or award of TRDA derivative securities (Form 4, code A).
- Oct 23, 2025: Grant or award of QTTB derivative securities (Form 4, code A).
- Aug 5, 2025: Disposition to issuer transaction of VIGL shares (Form 4, code D).
Other insiders filing for Q32 Bio Inc. (QTTB)
- Morrison Jodie Pope, CEO
- Violette Shelia M., Chief Scientific Officer
- Kalowski Lee, CFO and President
- TZIANABOS ARTHUR, Director
- Lundberg Sven Ante, Director
- LAPORTE KATHLEEN, Director